BowTiedBiotech 🧪🔬🧬 (@bowtiedbiotech) 's Twitter Profile
BowTiedBiotech 🧪🔬🧬

@bowtiedbiotech

Daily Biotech Updates: Public & Private Market Updates, Company Building, Financing, Exit Strategies, & Emerging Science Trends | Current: Janitor at Biotech VC

ID: 1462941795520638981

linkhttps://linktr.ee/bowtiedbiotech calendar_today23-11-2021 00:31:29

23,23K Tweet

17,17K Followers

596 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358
BowTiedBiotech 🧪🔬🧬 (@bowtiedbiotech) 's Twitter Profile Photo
BowTiedBiotech 🧪🔬🧬
@bowtiedbiotech

2 months ago

Glorious. They are going to get an earful re how USA can stay competitive with China and Australia for clinical development. Could be a massive positive benefit if feedback is internalized and USA returns to being the default for fast/cheap clinical work. FDA2.0 what a

BowTiedBiotech 🧪🔬🧬 (@bowtiedbiotech) 's Twitter Profile Photo
BowTiedBiotech 🧪🔬🧬
@bowtiedbiotech

2 months ago

🚨 New Phase 3 Obesity Data from China Innovent’s mazdutide (GLP-1 + glucagon) just hit -14% weight loss at 48 weeks in Chinese adults with obesity. That’s strong, but still trails global leaders: 🔹 Tirzepatide: –22.5% 🔹 Retatrutide: –24.2% 🔹 Semaglutide: –15% ➡️ Only ~50%

🚨 New Phase 3 Obesity Data from China Innovent’s mazdutide (GLP-1 + glucagon) just hit -14% weight loss at 48 weeks in Chinese adults with obesity. That’s strong, but still trails global leaders: 🔹 Tirzepatide: –22.5% 🔹 Retatrutide: –24.2% 🔹 Semaglutide: –15% ➡️ Only ~50%